$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[미국특허] Drug-eluting intravascular prostheses and methods of use 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61F-002/06
출원번호 US-0455521 (2009-06-02)
등록번호 US-8088160 (2012-01-03)
발명자 / 주소
  • Flugelman, Moshe
출원인 / 주소
  • Multi-Gene Vascular Systems Ltd. (“MGVS”)
대리인 / 주소
    Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보 피인용 횟수 : 1  인용 특허 : 50

초록

The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated

대표청구항

1. A method of treating a vascular disease or disorder by simultaneously inhibiting vessel blockage and enhancing recovery of the vessel wall following an intravascular intervention, the method comprising: a) placing a stent within a vessel of a subject in need thereof, wherein said stent is coated

이 특허에 인용된 특허 (50) 인용/피인용 타임라인 분석

  1. Leder Philip (Chestnut Hill MA) Muller William J. (Cambridge MA), Animal model for benign prostatic disease.
  2. Rubenstein Kenneth Edward (Palo Alto CA) Leute Richard K. (Sunnyvale CA), Antibody steric hindrance immunoassay with two antibodies.
  3. Frossard Philippe M. (Palo Alto CA), Apo AI/CIII genomic polymorphisms predictive of atherosclerosis.
  4. Flugelman,Moshe, Artificial vascular grafts, their construction and use.
  5. Ding Ni, Balloon expandable braided stent with restraint.
  6. Quertermous Thomas (Cambridge MA) Lee Mu-En (Boston MA), Cell specific gene regulators.
  7. Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
  8. Weinshank Richard L. (New York NY) Branchek Theresa (Teaneck NJ) Hartig Paul R. (Mahwah NJ), DNA encoding a human 5-HT1F receptor, vectors, and host cells.
  9. Dinh Thomas Q. (Minnetonka MN) Tuch Ronald J. (Plymouth MN) Schwartz Robert S. (Rochester MN), Drug eluting stent.
  10. Shulze, John E.; Betts, Ronald E.; Savage, Douglas R., Drug-delivery endovascular stent and method for treating restenosis.
  11. Flugelman, Moshe, Drug-eluting intravascular prostheses and methods of use.
  12. Udipi, Kishore; Cheng, Peiwen; Patel, Kaushik; Sundar, Rangarajan, Drug-polymer coated stent with pegylated styrenic block copolymers.
  13. Uzgiris Egidijus E. (Schenectady NY), Electrophoretic method of detecting antigen-antibody reaction.
  14. Gaulton Glen ; Park Ben Ho, Endothelial cell tropic compositions and methods of making and using the same.
  15. Flugelman,Moshe, Endothelial cells engineered to express or overexpress fibulin-5 and a growth factor.
  16. Schwartz Robert J. ; DeMayo Franco J. ; O'Malley Bert W., Expression vector systems and method of use.
  17. Ullman Edwin F. (Atherton CA) Schwarzberg Moshe (Palo Alto CA), Fluorescence quenching with immunological pairs in immunoassays.
  18. Kenneth A. Thomas, Jr. ; Richard L. Kendall ; Corey K. Goldman ; William R. Huckle ; Andrew J. Bett, Gene therapy for inhibition of angiogenesis.
  19. Breitbart Arnold S. ; Grande Daniel S. ; Mason James M., Genetic engineering of cells to enhance healing and tissue regeneration.
  20. Mulligan Richard C. (Lincoln MA) Cohen Lawrence K. (Oakland CA) Rafield Lori F. (San Fransisco CA) Birinyi Louis K. (Boston MA) Callow Allan D. (St. Louis MO) Wilson James M. (Ann Arbor MI), Genetic modification of endothelial cells.
  21. Mulligan Richard C. ; Cohen Lawrence K. ; Birinyi Louis K. ; Wilson James M., Genetic modification of endothelial cells.
  22. Shaul, Yosef; Zemel, Romi, Hepatitis B virus binding proteins and uses thereof.
  23. Bandman Olga ; Corley Neil C. ; Guegler Karl J., Human extracellular matrix proteins.
  24. Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
  25. Simons Malcolm J. (Fryerstown AUX), Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes.
  26. Kaplan Aaron V. ; Simons Michael, Localized intravascular delivery of growth factors for promotion of angiogenesis.
  27. Ni Ding ; W. Scott Andrus, Medical device with sponge coating for controlled drug release.
  28. Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
  29. Williams Stuart K. (Wilmington DE) Jarrell Bruce E. (Philadelphia PA), Method of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial.
  30. James L. Kinsella ; Steven J. Sollot, Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
  31. Trojanowski John Q. (Philadelphia PA) Lee Virginia M-Y. (Philadelphia PA), Modified avidin-biotin technique.
  32. Bellet Dominique (Paris MA FRX) Wands Jack R. (Waban MA), Multiepitopic immunometric assay.
  33. Byrne Guerard W. (Hamden CT) Ruddle Frank H. (New Haven CT), Multiplex gene regulation.
  34. Sorge Joseph A. (San Diego CA), Mutagenesis testing using transgenic non-human animals carrying test DNA sequences.
  35. Schwartz Robert J. (Houston TX) DeMayo Franco J. (Houston TX) O\Malley Bert W. (Houston TX), Myogenic vector systems.
  36. Honjo, Tasuku; Tashiro, Kei; Nakamura, Tomoyuki, Polypeptides suppressing smooth muscle cell proliferation, the encoding cDNA, and related methods.
  37. Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Positive-negative selection methods and vectors.
  38. Mullis Kary B. (Kensington CA), Process for amplifying nucleic acid sequences.
  39. Altman, Peter A., Pulmonary vein stent and method for use.
  40. Piasio ; Roger N. ; Ryan ; James W. ; Woiszwillo ; James E., Reverse sandwich immunoassay.
  41. Igaki Keiji,JPX ; Tamai Hideo,JPX, Stent for liberating drug.
  42. Gusella James F. (Framingham MA), Test for Huntington\s disease.
  43. Wayne H. Kaesemeyer, Therapeutic mixture useful in inhibiting lesion formation after vascular injury.
  44. Krimpenfort Paulus J. A. (Amsterdam NLX) Berns Antonius J. M. (Spaarndam NLX), Transgenic mice depleted in mature T-cells and methods for making transgenic mice.
  45. Cordell Barbara (Palo Alto CA), Transgenic mice displaying the amyloid-forming pathology of alzheimer\s disease.
  46. Leder Philip (Chestnut Hill MA) Stewart Timothy A. (San Francisco CA), Transgenic non-human mammals.
  47. Zilla, Peter Paul; Bezuidenhout, Deon; Dower, Theresa Yvonne, Transmural concentric multilayer ingrowth matrix within well-defined porosity.
  48. Miles Laughton E. M. (Stanford CA), Universal reagent 2-site immunoradiometric assay using labelled anti (IgG).
  49. Pratt Richard E. ; Dzau Victor J., VEGF gene transfer into endothelial cells for vascular prosthesis.
  50. Wagner Thomas E. (Athens OH) Chen Xiao-Zhuo (Athens OH), Virus-resistant transgenic mice.

이 특허를 인용한 특허 (1) 인용/피인용 타임라인 분석

  1. Kutryk, Michael John Bradley; Cottone, Jr., Robert J.; Rowland, Stephen M., Medical device with coating that promotes endothelial cell adherence.

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 특허

해당 특허가 속한 카테고리에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로